Controversial Issues of Pathogenesis and Lipid-Lowering Therapy of Atherosclerosis

Clinical pharmacology and therapy
doi 10.32756/0869-5490-2019-4-10-23
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pharmapress LLC

Related search

Lipid Lowering Therapy and Circulating PCSK9 Concentration

Journal of Atherosclerosis and Thrombosis
BiochemistryInternal MedicineCardiovascular MedicineCardiology
2017English

Three-Year Dynamics and Unsolved Problems of Lipid-Lowering Therapy

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2015English

Functional Evaluation of Lipid-Lowering Therapy by Pravastatin Response

Circulation
Cardiovascular MedicinePhysiologyCardiology
1998English

Pathogenesis of Atherosclerosis

BMJ
1964English

Pathogenesis of Atherosclerosis

BMJ
1964English

Regression of Atherosclerotic Renal Artery Stenosis With Aggressive Lipid Lowering Therapy

Journal of Human Hypertension
Internal Medicine
2001English

The Role of Aggressive Lipid Lowering Therapy for Coronary Artery Disease

Juntendo Medical Journal
2019English

Quality of Lipid-Lowering Therapy in Outpatient Practice: RECVAS Register Data

Profilakticheskaya Meditsina
Health PolicyPublic HealthOccupational HealthEnvironmental
2016English

Pharmacogenetics of Apolipoprotein E Gene During Lipid-Lowering Therapy: Lipid Levels and Prevention of Coronary Heart Disease

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy